- Healthcare 150
- Posts
- 22 Deals, $14.5B: Hospital M&A Reaccelerates Fast
22 Deals, $14.5B: Hospital M&A Reaccelerates Fast
Today we’re unpacking the rebound in hospital M&A as systems shift from retrenchment to selective consolidation.
Good morning, ! Today we’re unpacking the rebound in hospital M&A as systems shift from retrenchment to selective consolidation, private equity’s renewed conviction in medtech platforms, and how global nutraceutical markets are diverging across regions and growth trajectories.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
HEADLINE OF THE WEEK
Hospital M&A Reaccelerates as Systems Reset Post-Policy Shock
Hospital M&A is rebounding sharply, with 22 deals announced in Q1 2026 and total transacted revenue reaching $14.5B, a multi-year high. This follows a suppressed 2025, when deal volume fell to 46 transactions from 72 amid policy uncertainty and margin compression.
The composition of deals matters more than the volume. 15 of 22 transactions were divestitures, signaling that systems are not expanding indiscriminately. They are actively shedding underperforming assets to stabilize balance sheets and refocus on core markets.
At the same time, the return of mega-mergers and cross-market deals suggests a shift back toward scale-driven strategies. Larger systems are pursuing geographic diversification and payer leverage, while avoiding direct antitrust friction.
Why this matters now: the market is moving from defensive retrenchment to selective consolidation. Capital is flowing toward systems with clear operating discipline and partnership logic. For investors and operators, the window is reopening but with a higher bar. Execution, not ambition, is driving deal activity. (More)
PRESENTED BY SECTION
NEXT WEEK: Become a Head of AI in a Day – April 23 | Free Virtual Event
Join Section on 4/23 for a day of free AI transformation workshops designed to turn you into a winning AI leader.
You'll get frameworks for driving AI adoption, proficiency, and workflow automation – plus case studies from real enterprise leaders who’ve already gotten results from these methods.
DEAL OF THE WEEK
Private Equity Doubles Down on Medtech Platforms
Avanos Medical is going private in a $1.3B all-cash acquisition by American Industrial Partners, with shareholders receiving $25 per share, a 72.1% premium to the prior close and 82.8% above the 30-day average.
This is not a turnaround story. It is a control bet on a streamlined medtech platform. Avanos has spent recent years narrowing focus toward pain management, enteral feeding, and chronic care. The premium signals conviction that operational leverage and portfolio focus have already de-risked the asset.
The timing matters. Coming days after another large-scale private equity move in medtech, the deal reinforces a clear pattern. Financial sponsors are stepping in where strategics have pulled back, particularly in mid-cap device companies with stable cash flows but limited public market upside.
The playbook is familiar. Margin expansion, SKU rationalization, and bolt-on acquisitions. But the implication is broader. Public markets are undervaluing subscale medtech platforms, creating a widening arbitrage for private capital.
For operators and investors, the signal is clear. Execution-ready assets are migrating off public exchanges and into private equity portfolios. (More)
MICROSURVEY
To what extent are regulatory requirements impacting you organization's speed to market or operational efficiency? |
REGIONAL FOCUS
A Tale of Two Markets (and Three Speeds)
The global nutraceuticals market isn’t one market—it’s three playing out at different speeds. North America (36.1%) leads on scale and consumer adoption, powered by a deeply embedded supplement culture and a steady pipeline of functional food innovation.
Meanwhile, Europe (24.8%) plays the role of quality gatekeeper. Strict regulation has turned the region into a hub for science-backed formulations, particularly across probiotics and personalized nutrition.
But the real momentum sits in Asia-Pacific (19.9%)—the fastest-growing region, where digital health channels, rising incomes, and modernized traditional medicine are driving demand.
Emerging markets, including Latin America and MEA, round out the story with early but accelerating adoption.
Bottom line: The next wave of value won’t come from where nutraceuticals are established—but where they’re becoming essential. (More)
"The way to get started is to quit talking and begin doing."
Walt Disney